PF 489791

Drug Profile

PF 489791

Alternative Names: PF-00489791; PF-0489791; PF-489791

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Diabetic nephropathies; Hypertension; Postherpetic neuralgia; Pulmonary hypertension; Raynaud's disease; Renal failure

Most Recent Events

  • 04 May 2016 Discontinued - Phase-I for Diabetic nephropathies in Belgium (PO) (Pfizer pipeline, May 2016)
  • 04 May 2016 Discontinued - Phase-II for Diabetic nephropathies in Canada, South Korea, United Kingdom, Hong Kong, USA, Mexico, Malaysia, South Africa, Poland, Sweden, Denmark, Slovakia, Australia, India, Serbia (PO) (Pfizer pipeline, May 2016)
  • 17 Jun 2015 Phase-II development for Diabetic nephropathies is ongoing in World
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top